Carbapenem-resistant enterobacteriaceae (CRE)

Carbapenem-resistant enterobacteriaceae (CRE) is a topic covered in the Guide to Diagnostic Tests.

To view the entire topic, please or .

Emergency Central is a collection of disease, drug, and test information including 5-Minute Emergency Medicine Consult, Davis’s Drug, McGraw-Hill Medical’s Diagnosaurus®, Pocket Guide to Diagnostic Tests, and MEDLINE Journals created for emergency medicine professionals. Explore these free sample topics:

-- The first section of this topic is shown below --

Organism

Carbapenem-resistant enterobacteriaceae (CRE)

Carbapenemase production in the Enterobacteriaceae was unknown until early 2000s. Almost all carbapenem-resistant isolates were sporadic cases of hyperproduction of a beta-lactamase (AmpC or ESBL) combined with porin loss.

In 2001, there was the first report of carbapenem-resistant Klebsiella pneumoniae ; it carried a new carbapenemase, KPC enzyme.

New Delhi metallo-beta-lactamase (NDM1) has been described in patients infected with Escherichia coli or Klebsiella pneumoniae during surgery in India and Pakistan.

Outbreaks have been seen worldwide since 2003 of OXA-48 carbapenemase in K. pneumoniae , resulting in resistance to all beta-lactams.

-- To view the remaining sections of this topic, please or --

Organism

Carbapenem-resistant enterobacteriaceae (CRE)

Carbapenemase production in the Enterobacteriaceae was unknown until early 2000s. Almost all carbapenem-resistant isolates were sporadic cases of hyperproduction of a beta-lactamase (AmpC or ESBL) combined with porin loss.

In 2001, there was the first report of carbapenem-resistant Klebsiella pneumoniae ; it carried a new carbapenemase, KPC enzyme.

New Delhi metallo-beta-lactamase (NDM1) has been described in patients infected with Escherichia coli or Klebsiella pneumoniae during surgery in India and Pakistan.

Outbreaks have been seen worldwide since 2003 of OXA-48 carbapenemase in K. pneumoniae , resulting in resistance to all beta-lactams.

There's more to see -- the rest of this topic is available only to subscribers.